Evercore ISI initiated coverage on Caris Life Sciences with a new price target
$CAI
Medical Specialities
Health Care
Evercore ISI initiated coverage of Caris Life Sciences with a rating of Outperform and set a new price target of $33.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 4/13/2026 | $28.00 | Buy | Jefferies |
| 4/10/2026 | $21.00 | Neutral | Piper Sandler |
| 4/1/2026 | $27.00 | Buy | Goldman |
| 2/17/2026 | $26.00 | Outperform | Robert W. Baird |
| 12/2/2025 | $28.00 | Hold | Canaccord Genuity |
| 7/14/2025 | $31.00 | Buy | BofA Securities |
| 7/14/2025 | $31.00 | Overweight | Analyst |
Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphomaIRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-nega
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies. Molecular profiling reports from most
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi
Wolfe Research resumed coverage of Caris Life Sciences with a rating of Peer Perform
Jefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00
Piper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
Revenue growth of 79% driven by strong performance in molecular profiling servicesIRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsReported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corres
IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion
IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)